FDA-approved Hormones & metabolism

Mecasermin

Mecasermin is an IGF-1 (recombinant). It is filed in this library under hormones & metabolism, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Mecasermin has an FDA-approved product on the U.S. market, marketed as Increlex under application BLA021839.

The current label is held by Ipsen Biopharmaceuticals, Inc.

From the FDA label

What Mecasermin is approved to treat

(mecasermin) injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Limitations of use: INCRELEX is not a substitute to GH for approved GH indications. Severe Primary IGF-1 Deficiency (Primary IGFD) INCRELEX is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with: severe primary IGF-1 deficiency or growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Severe Primary IGF-1 deficiency (IGFD) is defined by: height standard deviation score ≤ –3.0 and basal IGF-1 standard deviation score ≤ –3.0 and normal or elevated growth hormone (GH).Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Mecasermin, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on hormones & metabolism

Markers on this pathway

What is measured when the growth hormone axis is assessed

Mecasermin's FDA-approved label indicates it for acromegaly or for a growth disorder, which are assessed on this axis. These are the markers clinicians use when assessing the growth hormone axis. They are listed here so you can read about them, not as a statement that Mecasermin changes any of them.

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Mecasermin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides